CRISPR vs Epigenetic Editing
CRISPR permanently alters DNA sequence, but a new wave of epigenetic editing technologies can silence or activate genes without changing a single DNA letter. Epigenetic editors use deactivated Cas9 (dCas9) fused to chromatin-modifying domains to add or remove chemical marks (methylation, acetylation) that control gene expression — effectively turning genes on or off reversibly. Tune Therapeutics is leading this approach into the clinic, while established CRISPR companies continue to advance permanent DNA editing. The key question: when is permanent better, and when do you want a reversible off-switch?
Last updated: March 30, 2026
CRISPR Gene Editing (Permanent DNA Changes)
CRISPR-Cas9 and its derivatives (base editing, prime editing) make permanent changes to the DNA sequence — cutting, converting bases, or inserting/deleting nucleotides. Once edited, the change is inherited by all daughter cells and cannot be undone.
Epigenetic Editing (Reversible Gene Control)
Uses a deactivated Cas9 (dCas9) — which binds DNA but does not cut it — fused to epigenetic effector domains (DNMT3A for silencing, p300/TET1 for activation) to add or remove chemical marks that control gene expression. The DNA sequence remains unchanged; only the regulatory marks are modified.
Key Specifications
| Feature | CRISPR Gene Editing (Permanent DNA Changes) | Epigenetic Editing (Reversible Gene Control) |
|---|---|---|
| Mechanism | Permanent DNA sequence modification (cut, convert, insert/delete) | Chemical modification of chromatin (methylation, acetylation) without DNA sequence change |
| Reversibility | Irreversible — permanent change to genome | Reversible — epigenetic marks can be removed or modified |
| Duration of effect | Lifelong (inherited by daughter cells) | Months to potentially years (durability under investigation) |
| DNA damage | Yes — DSBs (Cas9), nicks (base/prime editors) | None — dCas9 does not cut DNA |
| Off-target consequences | Permanent mutations at off-target sites | Transient gene expression changes (not permanent mutations) |
| FDA-approved therapies | 1 — Casgevy (Dec 2023) | 0 — clinical trials beginning 2026 |
| Active clinical trials | 100+ (CRISPR, base editing, prime editing combined) | ~1-3 (Tune Therapeutics lead programs) |
| Key companies | CRISPR Therapeutics, Intellia, Beam, Prime Medicine, Editas | Tune Therapeutics, Chroma Medicine, Omega Therapeutics |
| Best suited for | Diseases caused by gain-of-function mutations, gene knockout, permanent correction | Diseases where reversible silencing is preferred — chronic infections (HBV), pain, inflammatory conditions |
| Re-dosing needed | No — one-time treatment | Possibly — depends on durability of epigenetic marks |
CRISPR Gene Editing (Permanent DNA Changes)
Advantages
- FDA-approved: Casgevy (Dec 2023) for SCD/thalassemia — proven clinical and commercial path
- Permanent one-time cure: edit persists for life, no re-dosing needed (Intellia nex-z: 93% TTR knockdown at 3+ years)
- 100+ active clinical trials across multiple diseases and editing modalities
- Diverse toolkit: Cas9 (knockout), base editing (transitions), prime editing (any small edit) — right tool for each job
- In vivo delivery validated: Intellia lonvo-z Phase 3 complete, BLA target H2 2026
Limitations
- Irreversible: if an edit causes unexpected problems, it cannot be undone
- Double-strand breaks (Cas9) risk chromosomal rearrangements and large deletions
- Off-target permanent mutations — even rare off-targets are permanent
- Germline editing risk: unintended edits to reproductive cells could be inherited
- Higher regulatory bar due to irreversibility — extensive long-term safety monitoring required
Epigenetic Editing (Reversible Gene Control)
Advantages
- Reversible: gene silencing or activation can potentially be undone — critical safety advantage over permanent editing
- No DNA cutting: zero risk of double-strand breaks, chromosomal rearrangements, or permanent off-target mutations
- Tune Therapeutics advancing programs into clinic: TUNE-401 (chronic Hepatitis B) IND filed, Phase 1 planned 2026
- Durable silencing demonstrated: single-dose epigenetic silencing sustained for months in preclinical models
- Can silence entire gene regulatory regions — effective for repeat expansions and complex regulatory elements that are hard to target with traditional CRISPR
Limitations
- No FDA-approved epigenetic editing therapies — earliest clinical data expected 2026-2027
- Durability uncertain in humans: will epigenetic marks persist long-term, or will they need re-application?
- Fewer clinical programs than CRISPR — Tune Therapeutics is the primary clinical-stage company
- Large protein complex (dCas9 + effector domain) — delivery challenges similar to other CRISPR tools
- Reversibility is a double-edged sword: if the effect wears off, patients may need re-dosing
The Verdict
CRISPR and epigenetic editing are not direct competitors — they address fundamentally different therapeutic needs. CRISPR is the right choice when you want a permanent, one-time cure: sickle cell disease, hereditary angioedema, transthyretin amyloidosis. The clinical track record (FDA-approved Casgevy, 100+ trials) and durable efficacy data (3+ years) are unmatched. Epigenetic editing is the right choice when reversibility is a feature, not a bug: silencing Hepatitis B without permanently altering hepatocyte DNA, controlling pain pathways with the option to reverse if needed, or modulating gene expression in conditions where the optimal dose may change over time. Tune Therapeutics' entry into the clinic in 2026 will be a landmark test of whether epigenetic editing can deliver durable silencing in humans without permanent DNA changes. If successful, the field gains a powerful new paradigm: the ability to control gene expression with a reversible off-switch, complementing CRISPR's permanent on/off approach.
Sources & References
- [1]Tune Therapeutics pipeline and IND filings
- [2]Epigenetic editing for gene silencing (Nature Reviews Genetics)
- [3]dCas9-based epigenome editing tools (Nature Methods)
- [4]Chroma Medicine epigenetic editing platform
- [5]Casgevy FDA approval and clinical data
- [6]Intellia nex-z 3-year durability
- [7]Epigenetic editing in chronic HBV (preclinical)